Anti-CD20 antibody composition
JP2025520153A5Pending Publication Date: 2026-06-08TG THERAPEUTICS INC +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- TG THERAPEUTICS INC
- Filing Date
- 2023-05-31
- Publication Date
- 2026-06-08
AI Technical Summary
Technical Problem
Existing therapeutic monoclonal antibodies (mAbs) exhibit heterogeneity due to post-translational modifications (PTMs) that affect pharmacokinetic and pharmacodynamic properties and clinical efficacy, necessitating control of PTMs to ensure consistent product quality and safety.
Method used
A population of anti-CD20 antibodies with specified N-glycan profiles, including 20-40% fucosylated and 10-20% galactosylated glycans, is produced to maintain consistent product quality and enhance clinical efficacy.
Benefits of technology
The specified N-glycan profile enhances antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, improving therapeutic efficacy and reducing immunogenicity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
A population of anti-CD20 antibody proteins having a translated modification within a specified range is provided herein. Also provided are methods of using and making such populations of anti-CD20 antibody proteins.
Need to check novelty before this filing date? Find Prior Art